For the year ending 2025-12-31, APRE has $15,933,401 in assets. $14,599,347 in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 14,599,347 | |||
| Prepaid expenses and other current assets | 961,899 | |||
| Total current assets | 15,561,246 | |||
| Property and equipment, net | 59,807 | |||
| Restricted cash | 41,186 | |||
| Other noncurrent assets | 271,162 | |||
| Total assets | 15,933,401 | |||
| Accounts payable | 713,668 | |||
| Accrued expenses | 2,050,690 | |||
| Total current liabilities | 2,764,358 | |||
| Series a convertible preferred stock, 0.001 par value, 40,000,000 shares authorized 31,194 and 56,227 shares issued and outstanding at december 31, 2025 and december 31, 2024, respectively | 727,361 | |||
| Common stock, 0.001 par value, 400,000,000 shares authorized, 8,192,538 and 5,481,055 shares issued and outstanding at december 31, 2025 and december 31, 2024, respectively | 8,192 | |||
| Additional paid-in capital | 356,709,645 | |||
| Accumulated other comprehensive loss | -10,634,714 | |||
| Accumulated deficit | -333,641,441 | |||
| Total stockholders' equity | 12,441,682 | |||
| Total liabilities and stockholders' equity | 15,933,401 | |||
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)